Skip to main content
. 2011 Sep 5;2(6):1047–1052. doi: 10.3892/etm.2011.349

Figure 6.

Figure 6.

Tumor and subcutaneous tissue in (A–C) bevacizumab- and (D–F) IgG-administered mice bearing QGP-1 cells. (A and B) H&E staining, (B and E) CD-34 staining and (C and F) Ki-67 staining. CD-34 immunoreactivity in the cancerous area in tumors of bevacizumab-administered mice was stronger than that of the IgG-administered mice.